M. Kunst

518 total citations
9 papers, 257 citations indexed

About

M. Kunst is a scholar working on Genetics, Molecular Biology and Cancer Research. According to data from OpenAlex, M. Kunst has authored 9 papers receiving a total of 257 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 4 papers in Molecular Biology and 4 papers in Cancer Research. Recurrent topics in M. Kunst's work include Glioma Diagnosis and Treatment (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Cancer Research and Treatments (2 papers). M. Kunst is often cited by papers focused on Glioma Diagnosis and Treatment (5 papers), Cancer, Hypoxia, and Metabolism (4 papers) and Cancer Research and Treatments (2 papers). M. Kunst collaborates with scholars based in Germany and India. M. Kunst's co-authors include Reimar Schlingensiepen, Karl‐Hermann Schlingensiepen, Wolfgang Brysch, Franziska Wollnik, Thomas Herdegen, W. Seifert, K.-H. Schlingensiepen, Ella Magal, W. Brysch and Peter Hau and has published in prestigious journals such as Journal of Clinical Oncology, Cellular and Molecular Neurobiology and Developmental Genetics.

In The Last Decade

M. Kunst

9 papers receiving 251 citations

Peers

M. Kunst

MB

CMN

ONCOL

DN

CR

Anne Järve Germany

Christine Jack United States

Meifan Chen United States

John R. Jacob United Kingdom

Naguissa Bostaille Belgium

Lanlin Hu China

Rod M. Feddersen United States

Junya Nakade Japan

Liang Shi United States

Mabel Teo Singapore

Anne Järve Germany

M. Kunst

212 ×1.3

MB

88 ×0.9

CMN

31 ×0.5

ONCOL

55 ×1.7

DN

32 ×1.1

CR

Citations per year, relative to M. Kunst M. Kunst (= 1×) peers Anne Järve

Countries citing papers authored by M. Kunst

Since Specialization

Citations

This map shows the geographic impact of M. Kunst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Kunst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Kunst more than expected).

Fields of papers citing papers by M. Kunst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Kunst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Kunst. The network helps show where M. Kunst may publish in the future.

Co-authorship network of co-authors of M. Kunst

This figure shows the co-authorship network connecting the top 25 collaborators of M. Kunst. A scholar is included among the top collaborators of M. Kunst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Kunst. M. Kunst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Kunst, M., et al.. (2019). Two cases of hepatitis-associated aplastic anemia. Practical medicine. 17(8). 118–120. 1 indexed citations

2.

Bogdahn, Ulrich, В. Е. Парфенов, M. Kunst, et al.. (2006). Results of G004, a phase IIb study in recurrent glioblastoma patients with the TGF-b2 targeted compound AP 12009. Journal of Clinical Oncology. 24(18_suppl). 1553–1553. 5 indexed citations

3.

Hau, Peter, Günther Stockhammer, M. Kunst, et al.. (2006). Results of G004, a phase IIb actively controlled clinical trial with the TGF-b2 targeted compound AP 12009 for recurrent anaplastic astrocytoma. Journal of Clinical Oncology. 24(18_suppl). 1566–1566. 5 indexed citations

4.

Hau, Peter, M. Kunst, Josef Pichler, et al.. (2005). Targeted downregulation of TGF-beta2 as immunotherapy for high-grade glioma: A phase IIb study. Journal of Clinical Oncology. 23(16_suppl). 1537–1537. 3 indexed citations

5.

Bogdahn, Ulrich, Peter Hau, Alexander Brawanski, et al.. (2004). Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP 12009. Journal of Clinical Oncology. 22(14_suppl). 1514–1514. 17 indexed citations

6.

Bogdahn, Ulrich, Peter Hau, Alexander Brawanski, et al.. (2004). Specific therapy for high-grade glioma by convection-enhanced delivery of the TGF-β2 specific antisense oligonucleotide AP 12009. Journal of Clinical Oncology. 22(14_suppl). 1514–1514. 4 indexed citations

7.

Brysch, W., et al.. (1994). Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation.. PubMed. 1(2). 99–105. 27 indexed citations

8.

Schlingensiepen, Karl‐Hermann, Franziska Wollnik, M. Kunst, et al.. (1994). The role of Jun transcription factor expression and phosphorylation in neuronal differentiation, neuronal cell death, and plastic adaptationsin vivo. Cellular and Molecular Neurobiology. 14(5). 487–505. 112 indexed citations

9.

Schlingensiepen, Karl‐Hermann, et al.. (1993). Opposite functions of Jun‐B and c‐jun in growth regulation and neuronal differentiation. Developmental Genetics. 14(4). 305–312. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact